Johnson & Johnson's most recent earnings data showed revenues and earnings per share growing more robustly than analysts anticipated. However,…
McAlinden Research PartnersApril 18, 2023
Throughout the past month, legislators in nearly half a dozen US states have introduced bills focused on reforming laws that…
McAlinden Research PartnersJanuary 30, 2023
Shares of biotechnology firms focused on gene editing were slammed this week by an FDA hold placed on Verve Therapeutics'…
McAlinden Research PartnersDecember 8, 2022
Three pharma giants are in the running to purchase Horizon Therapeutics in what will likely be a larger deal than…
McAlinden Research PartnersDecember 1, 2022
Germany will soon legalize the acquisition and purchase of up to 30 grams of cannabis for recreational purposes, following several…
McAlinden Research PartnersOctober 27, 2022
The US's first marketed CRISPR drug may be set to make its debut in a year or less, following CRISPR…
McAlinden Research PartnersSeptember 29, 2022
M&A activity is picking up among pharmaceutical firms with large cash balances. Pfizer and Amgen have each closed a multi-billion…
McAlinden Research PartnersAugust 9, 2022
Pharma giants Pfizer and Moderna just secured multi-billion dollar deals to supply the US government with more than 170 million…
McAlinden Research PartnersAugust 1, 2022
Psychedelic medicine, focused on alternative mental health therapies that utilize drugs like LSD, MDMA and psilocybin, is becoming increasingly popular…
McAlinden Research PartnersJuly 18, 2022
